15 / 35
Infectious Diseases 2018
Journal of Prevention and Infection Control
ISSN: 2471-9668
Page 54
June 07-08, 2018
London, UK
8
th
Edition of International Conference on
Infectious Diseases
Introduction:
Tuberculosis (TB) is a leading cause of death and
became one of the biggest threats to the world. Improvement of
its treatment strategies and possibly to reduce drug resistance
monitoring and evaluations (M&E) of chemotherapeutic
responses are necessary.
Objective:
To evaluate interferon gamma release assay (IGRA) as
a tool for M&E of the efficacy of chemotherapeutic intervention
of active TB.
Methods:
Institutional based prospective longitudinal cohort
study design was used. Patients positive for acid fast bacilli stain
(AFB), culture and/or GeneXpertMTB/RIF assaywere recruited for
the study. IGRA was used to evaluate IFN-ɣ response to treatment.
Results:
The recruited 21 patients had the mean age of 35.5,
median 33 and range was 23-56 years. All patients were cured
after the treatment. The mean of the concentration (IU) of IFN-γ
response showed decreasing trends from baseline (mean+SD,
2.09+1.09) to the end of the treatment (mean+SD, 0.23+0.20). The
patients’ individual baseline IFN-γ concentration had differences
and being similar at the end of their treatment. Repeated IFN-ɣ
responses had been evaluated for associations between each
measurements and showed statistical significance only between
two pairs (P<0.001). In this study, IFN-ɣ response to tuberculosis
chemotherapeutic intervention was not affected by any of the
socio-demographic factors of the study participants (P>0.05).
Conclusions:
The decreasing trend in IFN-ɣ response following
successful anti-TB may have a value as a tool for M&E of the
efficacy of chemotherapeutic intervention for active TB.
adanewrk@yahoo.comEvaluation of interferon gamma release assay as a clinical
tool for monitoring and evaluation of anti-tuberculosis
chemotherapy
Adane Worku
1
, Rembert Piper
2
, Girmay Medhin
1
and
Gobena Ameni
1
1
Addis Ababa University, Ethiopia
2
J Craig Venter Institute, Rockville, USA
J Prev Infect Cntrol 2018, Volume 4
DOI: 10.21767/2471-8084-C1-003